Literature DB >> 6683731

Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study.

L M Shapiro, W J McKenna.   

Abstract

The distribution of left ventricular hypertrophy was assessed by M-mode and two-dimensional echocardiography in 89 patients with hypertrophic cardiomyopathy. Myocardial thickness was measured in the septum and the free and posterior wall in both the proximal and distal left ventricle. All patients had at least one myocardial region that was hypertrophied. The predominant pattern of hypertrophy was defined as symmetric (31%), asymmetric septal (55%) and distal ventricular (14%). The spectrum of wall thickness measurements between patients with symmetric hypertrophy was wide (1.5 to 4.5 cm) and was not related to age. In patients with asymmetric septal hypertrophy, the distribution of hypertrophy conformed to previously described patterns; hypertrophy was localized to the anterior septum (14%) or the anterior and posterior septum (35%) or involved both the septum and the left ventricular free wall (51%). The patients with distal ventricular hypertrophy had marked papillary muscle thickening, and only 1 of 12 patients could be correctly diagnosed using M-mode echocardiography. The proportion of patients with symmetric and distal ventricular hypertrophy was greater than that reported when patients are selected on the basis of M-mode diagnostic criteria. This reflects the limitations of the M-mode technique in the assessment of left ventricular hypertrophy and suggests that the recognition and understanding of hypertrophic cardiomyopathy have been biased by patients with asymmetric septal hypertrophy who previously were most readily identified.

Entities:  

Mesh:

Year:  1983        PMID: 6683731     DOI: 10.1016/s0735-1097(83)80269-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  44 in total

1.  Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy.

Authors:  K Prasad; J Atherton; G C Smith; W J McKenna; M P Frenneaux; P Nihoyannopoulos
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

Review 2.  The role of echocardiographic deformation imaging in hypertrophic myopathies.

Authors:  Maja Cikes; George R Sutherland; Lisa J Anderson; Bart H Bijnens
Journal:  Nat Rev Cardiol       Date:  2010-05-11       Impact factor: 32.419

3.  Hypertrophic cardiomyopathy in the elderly.

Authors:  L M Shapiro
Journal:  Br Heart J       Date:  1990-05

4.  Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy.

Authors:  S Cox; A C O'Donoghue; W J McKenna; A Steptoe
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

Review 5.  Problems in diagnosis and management of hypertrophic cardiomyopathy.

Authors:  O Odemuyiwa; W J McKenna
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

6.  Hypertrophic cardiomyopathy: one disease or several?

Authors:  M J Davies
Journal:  Br Heart J       Date:  1990-05

7.  Endogenous endothelin 1 mediates angiotensin II-induced hypertrophy in electrically paced cardiac myocytes through EGFR transactivation, reactive oxygen species and NHE-1.

Authors:  María V Correa; Mariela B Nolly; Claudia I Caldiz; Gladys E Chiappe de Cingolani; Horacio E Cingolani; Irene L Ennis
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

8.  Hypertrophic cardiomyopathy simulating an infiltrative myocardial disease.

Authors:  A Frustaci; F Loperfido; F Pennestrì
Journal:  Br Heart J       Date:  1985-09

9.  Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts.

Authors:  Shinsuke Hanatani; Yasuhiro Izumiya; Seiji Takashio; Sunao Kojima; Megumi Yamamuro; Satoshi Araki; Taku Rokutanda; Kenichi Tsujita; Eiichiro Yamamoto; Tomoko Tanaka; Shinji Tayama; Koichi Kaikita; Seiji Hokimoto; Seigo Sugiyama; Hisao Ogawa
Journal:  Heart Vessels       Date:  2013-03-23       Impact factor: 2.037

10.  Cardiomyopathy of glycogen storage disease type III.

Authors:  J S Carvalho; E E Matthews; J V Leonard; J Deanfield
Journal:  Heart Vessels       Date:  1993       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.